Syndax Pharmaceuticals News and Activities
Presence
Syndax Pharmaceuticals develops and sells medicines for cancer and other serious diseases. Its products and research programs support hospitals, cancer specialists, and patients who need targeted drug treatments.
Syndax Pharmaceuticals products and services overview:
- Cancer medicines
- Targeted therapies
- Blood cancer drugs
- Clinical research
Revenue: ~$100 million
Employees: 300
Headquarters: Waltham, United States (USA)
Syndax Pharmaceuticals is one of the...
Syndax Pharmaceuticals is a company listed under the stock ticker SNDX (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Syndax Pharmaceuticals
- Michael Metzger, Director and Chief Executive Officer
- Jennifer Jarrett, Director
- Martin Huber, Director
Create your alert
to follow the executive moves at Syndax Pharmaceuticals.
Pharmaceuticals
Syndax Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Syndax Pharmaceuticals
- Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
- Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
- Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
- View more press releases Close
Social media about Syndax Pharmaceuticals
- Syndax Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Syndax Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
